Eczema treatment breakthrough? new dosing could mean fewer shots
NCT ID NCT06526182
First seen May 01, 2026 · Last updated May 11, 2026 · Updated 2 times
Summary
This study tests the drug lebrikizumab in 520 adults and teens (ages 12+) with moderate-to-severe eczema. The goal is to see if a new, less frequent dosing schedule (every 12 weeks) works as well as the current one (every 4 weeks) at controlling skin symptoms. Participants will receive the drug for 24 weeks, and then be assigned to one of the two dosing schedules for another 36 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Consorci Hospital General Universitari de València
Valencia, Spain
-
Hospital General Universitario Dr. Balmis
Alicante, Spain
-
Hospital Universitario Clínico San Cecilio
Granada, Spain
-
Hospital del Mar - Parc de Salut Mar
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.